Novel small molecule inhibition of IKK/NF-κB activation reduces markers of senescence and improves healthspan in mouse models of aging

Constitutive NF-kappa B activation is associated with cellular senescence and stem cell dysfunction and rare variants in NF-kappa B family members are enriched in centenarians. We recently identified a novel small molecule (SR12343) that inhibits IKK/NF-kappa B activation by disrupting the association between IKK beta and NEMO. Here we investigated the therapeutic effects of SR12343 on senescence and aging in three different mouse models. SR12343 reduced senescence-associated beta-galactosidase (SA-beta-gal) activity in oxidative stress-induced senescent mouse embryonic fibroblasts as well as in etoposide-induced senescent human IMR90 cells. Chronic administration of SR12343 to the Ercc1(-/Delta)/A and Zmpste24(-/-) mouse models of accelerated aging reduced markers of cellular senescence and SASP and improved multiple parameters of aging. SR12343 also reduced markers of senescence and increased muscle fiber size in 2-year-old WT mice. Taken together, these results demonstrate that IKK/NF-kappa B signaling pathway represents a promising target for reducing markers of cellular senescence, extending healthspan and treating age-related diseases.

Automated summary

Inhibiting NF-κ B activation with SR12343 shows promising results in reducing cellular senescence markers, improving muscle fiber size, and extending healthy lifespan. The therapeutic effects of SR12343 were observed in different mouse models, suggesting it as a potential treatment for reducing cellular senescence and aging-related diseases.